乳がん術前・術後補助化学療法に対する相対用量強度の影響に関する研究

書誌事項

タイトル別名
  • Study on the Influence of Relative Dose Intensity on Neo Adjuvant Chemotherapy and Adjuvant Chemotherapy for Breast Cancer

この論文をさがす

抄録

<p>Maintaining Average Relative Dose Intensity (ARDI) in neo adjuvant chemotherapy and adjuvant chemotherapy in breast cancer leads to an improved therapeutic effect, but few patients have clear indicators.</p><p>In the study we report the effect of ARDI on the treatment effect in EC followed by weekly nab-PTX therapy. Our subjects were 48 patients with breast cancer who received EC followed by weekly nab-PTX therapy in neo adjuvant chemotherapy and adjuvant chemotherapy at Nihon University Itabashi Hospital between 2012 and 2017.</p><p>In the study we compared Disease-free survival (DFS) and adverse effect rates between the two groups of the ARDI ≥ 90% group and ARDI < 90% group.</p><p>The patients in the ARDI ≥ 90% group exhibited significant difference in 2 years DFS and 3 years DFS (2 years DFS: P = 0.0095, 3 years DFS: P = 0.0019) as compared to the ARDI < 90% group. In terms of the adverse effect incidence rate, pathological subtype by type DFS, there was no difference between the two groups. Maintaining ARDI at 90% or higher in this study leads to improvement of the therapeutic effect.</p>

収録刊行物

  • 医療薬学

    医療薬学 45 (8), 485-490, 2019-08-10

    一般社団法人日本医療薬学会

参考文献 (14)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ